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Abstract
Background: Familial Mediterranean fever is a genetic autoinflammatory disease most commonly affecting the
ethnic groups originating from around the Mediterranean Sea. Apoptosis plays an important role in down-
regulation of the inflammatory response by reducing the lifespan of activated immunocompetent cells. Thus,
increased apoptosis may be associated with pathogenesis of familial Mediterranean fever.
Methods: In the present study we determined the serum levels of apoptotic marker, Annexin A5, in familial
Mediterranean fever patients, within an attack and attack-free, in comparison to healthy subjects and assessed the
influence of colchicine treatment on this parameter. In addition, in all study subjects serum levels of C-reactive
protein and interleukine-1b, and the total leukocyte count were also determined.
Results: Our results demonstrated that pathogenesis of familial Mediterranean fever is characterized by the
increased levels of circulating Annexin A5, which is higher in patients within the attack and which associate with
the increased levels of C-reactive protein and interleukine-1b and total leukocyte count.
Conclusions: The results obtained indicate elevated rates of apoptosis of subpopulations of leukocytes involved in
autoinflammation and recurrent episodes of fever in familial Mediterranean fever. It was also revealed that regular
colchicine treatment sufficiently decreases the rate of apoptosis in familial Mediterranean fever patients by affecting
the intensity of autoinflammatory reactions.
Introduction
Familial Mediterranean fever (FMF; MIM 294100) is a
genetic autoinflammatory disease most commonly
affecting the ethnic groups originating from around the
Mediterranean Sea, including Armenians, North African
Arabs, Sephardic Jews, and Turks. It is the most preva-
lent hereditary periodic fever worldwide characterized
by self-limited recurrent episodes of fever (FMF attack)
and is often complicated by amyloidosis. FMF is caused
by mutations in MEFV gene coding for the protein
pyrin. Although the genetic defect is known, the
mechanisms by which this defect causes inflammatory
attacks are largely unclear [1,2].
Pyrin contains a 92-aminoacid N-terminal pyrin
domain that is shared by a number of other proteins
involved in apoptotic and inflammatory signaling path-
ways. The pyrin domain is a member of the six-helix
bundle, death-domain superfamily that includes death
domains, death effector domains, and caspase recruit-
ment domains (CARDs) involved in the protein-protein
interactions required for apoptosis or signaling through
NFB. Therefore, it is proposed that pyrin is likely a
part of regulatory pathway of inflammation and nor-
mally assists in keeping inflammation under control by
deactivating the immune response and uncontrolled
inflammation. Apoptosis plays an important role in
down-regulation of the inflammatory response by redu-
cing the lifespan of activated immunocompetent cells.
Thus, increased apoptosis may be associated with patho-
genesis of FMF [3-6].
Flow cytometry study indicated that neutrophil and
monocyte apoptosis is significantly increased in FMF
patients as compared to control subjects [7]. Since no dif-
ference in lymphocyte apoptosis between FMF patients
and norm was found [8], and animal studies demonstrated
decreased macrophage apoptosis in FMF [9], this finding
may indicate that FMF is an autoinflammation of certain
peripheral cells. On the other hand, this finding may also
reflect defect in apoptosis regulation in FMF-patients.
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Since 1972 colchicine treatment is the only prophy-
laxis against FMF attacks, related inflammatory episodes
and amyloidosis [1,2]. Colchicine prevents the activation
of neutrophils and development of amyloidosis through
inhibiting the assembly of microtubules and mitotic
spindle formation by binding b-tubulin [1,2]. However,
the exact way in which colchicine suppresses attacks is
unclear. Our recent study demonstrated that regular col-
chicine treatment result in suppression of the comple-
ment system, the major mediator of the inflammatory
immune response [10]. In the present study we deter-
mined the serum levels of apoptotic marker, Annexin
A5 (ANX-V), in FMF-patients within an attack and
attack-free in comparison to healthy volunteers group
and assessed the influence of colchicine treatment on
this parameter. In addition, in all study subjects serum
levels of C-reactive protein (CRP) and interleukine-1b
(IL-1b), and the total leukocyte count (TLC) were also
determined; and. correlation between all measured para-
meters was analyzed.
Materials and methods
Forty four FMF-affected subjects (female/male: 19/25;
mean age ± SD: 30.28 ± 10.57; within attack/attack free:
20/24) and 50 age- and sex-matched healthy volunteers
(controls) without family history of FMF or other auto-
inflammatory diseases were enrolled in this study. All
subjects were Armenians living in Armenia. Subjects
with concurrent diseases or conditions interfering with
the aim of this study, such as inflammatory, infectious,
or autoimmune diseases, vasculitis, myocardial infarc-
tion, cancer, hematological diseases, severe renal or liver
failure, gynecologic or urologic diseases, any surgical
interventions within the previous 12 months, and those
on immune-modulator drugs, were not included in the
study. The study was approved by the local Ethics Com-
mittee; all subjects gave informed consents to provide
5 ml of venous blood for this study. The patients were
recruited from the Department of Internal Diseases
(Hospital N1) of Yerevan State Medical University.
Among them, 21 were colchicine-free (12 of them were
colchicine-naïve, for the remainder of the patients col-
chicine-free interval was 2 years), 23 received colchicine
regularly for at least 2 last years prior to this study. Ten
patients had renal amyloidosis. The clinical diagnosis of
FMF was based on the Tel-Hashomer criteria. [11]. All
patients showed relevant to FMF pathogenic mutations
of pyrin gene, including M694V, V726A, M680I (G/A),
M680I (G/C), F479L, and E148Q. Most patients had
more than one of these mutations, and were heterozy-
gous for each mutation. Seven patients were homozy-
gous for M694V. Practically fasting blood samples were
collected by venipuncture at 9:00-10:00 a.m. in two
aliquotes. One was immediately used for measuring
TLC, another was kept on ice for 60 min, then centri-
fuged at 3000 g for 15 min at 4°C to separate serum.
The obtained serum samples were stored in aliquots at
-30°C and thawed immediately prior to use. Serum
levels of ANX-V and IL-1b were determined by ELISA
using commercially available kits (Hölzel Diagnostika
GmbH, Germany and Vektor-Best, Russia, respectively),
according to manufacturers’ instructions. Concentration
of CRP in the serum was measured by turbidimetric
method (Hmalyzer 2000, HUMAN, Germany). TLC was
measured by automated hematology analyzer. For data
analysis ordinal descriptive statistics and Student’s
unpaired two-tailed t-test with Welch’s correction (upon
comparing unequal variances) were applied using
“Graphpad Prism” (GraphPad Software Inc., USA) soft-
ware. P-values < 0.05 were considered to be significant.
Results
According to the results obtained significantly increased
serum levels of ANX-V were detected in all FMF patients
as compared to controls (M ± SD: 7.88 ± 3.23 vs 1.83 ±
0.53, p < 0.0001), with higher levels in the attack group
compared to attack free (M ± SD: 10.64 ± 2.72 vs 5.598 ±
1.11, p < 0.0001). Patients receiving regular colchicine
treatment have significantly lower levels of ANX-V in
comparison to those colchicine-free (6.341 ± 1.96 vs
9.567 ± 3.53, p < 0.0009). The results obtained are
summarized on Figures 1, 2.
All patients have significantly higher CRP level (M ±
SD: 59.17 ± 14.92 vs 1.5 ± 0.2, p < 0.0001), IL-1b level
(M ± SD: 5.281 ± 3.2 vs 2 ± 1.2, p < 0.002), and TLC
(M ± SD: 12800 ± 2621 vs 6400 ± 1032, p < 0.001) in
comparison to the healthy subjects, with higher values
in attack patients and lower in colchicine-free patients.
Discussion
ANX-V, belonging to a recently discovered family of pro-
teins, the annexins, has proven to be a useful tool in
detecting apoptotic cells, since it preferentially binds to
negatively charged phospholipids like phosphatidylserines
(PS) in the presence of Ca2+. ANX-V is an important
modulator of the immune response against PS-exposing
particles like apoptotic cells, necrotic cells, and certain
viruses. Loss of plasma membrane asymmetry, resulting
in the exposure of PS, is considered to be an early event
in apoptosis and is detected before morphological
changes associated with apoptosis have occurred and
before membrane integrity has been lost. The exposure
of PS is one major “eat me” signal for phagocytes of
apoptotic cells, which are normally cleared via an anti-
inflammatory pathway. ANX-V may interfere in vivo
with the immunosuppressive effects of apoptotic cells,
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bits apoptotic cell uptake by phagocytes [12,13].
ANX-V is produced by a variety of cells and is an in
vivo marker of cellular injury and death. Circulating
ANX-V can be released from the cells of the vascular
wall (endothelial cells, smooth muscle cells), from secre-
tor cells of the spleen and liver or from apoptotic parti-
cles derived from injured tissue, monocytes, lymphocytes,
etc. High blood levels of ANX- V reflect high rate of cell
death and the severity of cell damage [14,15].
The present study demonstrates that pathogenesis of
FMF is associated with the increased levels of circulating
ANX-V, especially in attack period, together with the
increased levels of CRP and IL-1b,a n dT L C .O u rd a t a
most probably reflect raised production of ANX-V as a
response to clear the unwanted inflammatory cells and
an increased rate of cell death in FMF. Higher levels of
ANX-V in FMF patients within attack may be consid-
ered as an explanation of the self-limited nature of the
FMF attacks [1,2]. As far as increased levels of circulat-
ing ANX-V were detected not only during FMF-attack
but also in attack-free period, this finding may also
reflect the chronic nature of disease-related inflamma-
tion, and inability of defective pyrin to keep inflamma-
tion under control [1,2]. The results obtained confirm
previous observation based upon flow-cytometry data
indicating increased rate of apoptosis of subpopulations
of leukocytes involved in autoinflammation and recur-
rent episodes of fever in FMF [7].
In addition, our results demonstrated that regular col-
chicine treatment sufficiently decreases the levels of
circulating ANX-V. This is probably due to suppressing
effect of colchicine on leukocyte degranulation/chemo-
taxis and production of the inflammatory mediators,
CRP and IL-1b, as revealed by this study, and on activity
of the complement cascade, as it was shown in our pre-
vious report [10].
Conclusions
Pathogenesis of FMF is characterized by the increased
levels of circulating ANX-V, which is higher in patients
within the attack and which reflect elevated rates of
apoptosis of subpopulations of leukocytes involved in
autoinflammation and recurrent episodes of fever, dis-
tinctive features of FMF. Regular colchicine treatment
sufficiently decreases the rate of apoptosis in FMF
patients by affecting the intensity of autoinflammatory
reactions.
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